CAMP4 Therapeutics financials
$3.91+1.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q4 '15 Feb 28 | Q3 '15 Nov 30 | Q2 '15 Aug 31 | Q1 '15 May 31 | Q4 '14 Feb 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $1.3M | $348.0K | $795.0K | $1.5M | $858.0K | $652.0K | $69.2M | $63.2M | $59.2M | $59.0M | $59.8M |
| Gross profit | $1.8M | $1.3M | $348.0K | $795.0K | $1.5M | $858.0K | $652.0K | $24.6M | $22.1M | $20.5M | $20.2M | $20.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 35.5% | 35.0% | 34.6% | 34.3% | 34.4% |
| Operating income | -$13.4M | -$13.1M | -$12.8M | -$13.7M | -$13.0M | -$13.1M | -$14.0M | $8.8M | $6.5M | $5.0M | $4.6M | $4.7M |
| Net income | -$33.5M | -$18.3M | -$40.3M | -$15.1M | -$12.6M | -$12.4M | -$13.3M | $6.5M | $4.0M | $3.3M | $2.7M | $3.1M |
| Net margin | −1884.8% | −1416.6% | −11575.9% | −1899.2% | −840.8% | −1449.1% | −2036.7% | 9.4% | 6.4% | 5.5% | 4.6% | 5.1% |
| Diluted EPS | $-0.58 | $-0.32 | $-0.75 | $-0.55 | $-0.62 | $-0.62 | $-0.77 | $0.18 | $0.11 | $0.09 | $0.07 | $0.09 |
| EBITDA | -$12.9M | -$12.6M | -$12.4M | -$12.7M | -$12.6M | -$12.7M | -$13.6M | $8.8M | $8.8M | $7.5M | $6.8M | $4.7M |
| Operating cash flow | -$12.7M | -$11.0M | $6.3M | -$11.2M | -$10.3M | -$14.3M | -$11.3M | $7.2M | $5.4M | $8.7M | $7.3M | $3.4M |
| Free cash flow | -$12.8M | -$11.0M | $6.3M | -$11.2M | -$10.3M | -$14.6M | -$11.6M | $4.6M | $3.9M | $6.8M | $5.9M | $2.7M |
| Diluted shares | 57.9M | 57.9M | 53.9M | 27.3M | 20.2M | 20.2M | 17.3M | 36.5M | 36.5M | 36.5M | 36.5M | 36.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $86.4M | $99.2M | $109.5M | $75.3M | $39.1M | $49.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $74.0K | $182.0K | $193.0K |
| Total assets | $93.4M | $105.5M | $117.8M | $86.4M | $51.3M | $62.8M |
| Total liabilities | $94.1M | $74.6M | $70.1M | $27.7M | $11.3M | $11.2M |
| Shareholders' equity | -$693.0K | $30.9M | $47.7M | $58.7M | $40.0M | $51.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology